cladribine

This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.

Sanofi licences Principia MS drug in $805m deal

The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.

Latest news

Merck mulls sale of consumer health division

The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of
Merck gets CHMP backing for long-delayed oral MS drug

Follow-up studies also revealed that oral cladribine could be stopped in year three and four without an increase in relapses. ... The company thinks oral cladribine has a key differentiator from its rivals, which require daily dosing.
Avelumab costs peg back profit at Merck KGaA

Avelumab and other pipeline candidates such as oral MS therapy cladribine have assumed even more importance for Merck since it abandoned plans to seek approval of evofosfamide in advanced soft tissue
Merck's pharma unit faces tougher 2017 as fertility boost recedes

Top of that list is oral MS therapy cladribine, which was submitted for approval in the EU in June, and according to Kuhnert is proceeding through regulatory review as expected.
Merck sees €2bn from new launches by 2022

Other than avelumab, Merck has just two other candidates in late-stage development, namely oral cladribine for multiple sclerosis (MS) and a biosimilar of AbbVie's TNF inhibitor Humira (adalimumab). ... Cladribine is closest to market having already been

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest appointments

XenoPort appoints chief medical officer

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor – Medical Education Agency – Bucks: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Medical Writer, e-learning/ training, London: Excellent Salary

Project Manager, Medical Communications, London: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Programme Executive: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer: Great salary and benefits

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager / Account Director: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editorial Director – Medical Education – Oxford: Negotiable

Scientific Director: Great salary and bebefits

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...